603669.SH
灵康药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 5.39
−1.64%Aug 14, 2026, 15:57 UTC
Lingkang Pharmaceutical reported its 2026 half-year results, with revenue of 257 million yuan, up 50.03% year-on-year, and net profit attributable to shareholders of 21.11 million yuan, turning from a loss to a profit.
Source:Aug 14, 2026, 10:54 UTC
Lingang Pharmaceutical announced its 2026 first-half results, reporting a net profit of 21.1127 million yuan, turning around from a loss in the prior year.
Source:Aug 12, 2026, 07:38 UTC
Lingang Pharmaceutical's subsidiary Lingang Pharma's product Huperzine A for injection (brand Ruilisu) was selected in a provincial alliance centralized procurement led by Henan Province, with a 2-year procurement cycle.